Rufinamide Tablets, USP 400 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo...

FDA Drug Recall #D-1088-2023 — Class II — July 21, 2023

Recall Summary

Recall Number D-1088-2023
Classification Class II — Moderate risk
Date Initiated July 21, 2023
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Aurobindo Pharma USA Inc.
Location East Windsor, NJ
Product Type Drugs
Quantity 48 bottles

Product Description

Rufinamide Tablets, USP 400 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-617-08

Reason for Recall

cGMP deviations: Batch was released prior to approval.

Distribution Pattern

USA nationwide

Lot / Code Information

Lot #: RB4023002A, Exp 02/2025

Other Recalls from Aurobindo Pharma USA Inc.

Recall # Classification Product Date
D-0492-2024 Class II Clorazepate Dipotassium Tablets, USP, 7.5 mg, a... Apr 24, 2024
D-0491-2024 Class II Clorazepate Dipotassium Tablets, USP, 3.75 mg, ... Apr 24, 2024
D-1171-2023 Class II Rasagiline Tablets 0.5mg, 30-count bottle, Rx o... Aug 2, 2023
D-1087-2023 Class II Rufinamide Tablets, USP 200 mg, packaged in 120... Jul 21, 2023
D-0765-2023 Class II Pain Reliever, Acetaminophen USP Caplets, 500 m... May 22, 2023

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.